Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study

Abstract Background Venetoclax (VEN) and azacitidine (AZA) are used to treat patients with newly diagnosed acute myeloid leukaemia (AML) who are unfit for intensive chemotherapy and those with relapsed or refractory AML. Understanding the real-world usage patterns and outcomes after VEN-AZA therapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie-Fei Bai, Ting Wang, Jiang-Tao Li, Chun-Li Zhang, Long Qian, Ya-Zi Yang, Xiao-Ya Yun, Jing-Jing Yin, Fei Zhao, Wei-Dong Ding, Bao-Li Xing, Shang-Yong Ning, Lei Pei, Xiao-Dong Xu, Hui Liu, Ru Feng
Format: Article
Language:English
Published: BMC 2025-06-01
Series:BMC Cancer
Subjects:
Acute myeloid leukemia
Hypomethylating agents
Venetoclax
Relapse
Refractory
Online Access:https://doi.org/10.1186/s12885-025-14167-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items